Výsledky vyhledávání - "Bruce Randazzo"

Akademický článek

Development of a patient-reported outcome questionnaire for use in adults with moderate-to-severe plaque psoriasis: The Psoriasis Symptoms and Signs Diary

Autor: Steven R. Feldman, Susan D. Mathias, Brad Schenkel, Hilary H. Colwell, Kelly McQuarrie, Bruce Randazzo, Chenglong Han

Publikováno v: Journal of Dermatology and Dermatologic Surgery, Vol 20, Iss 1, Pp 19-26 (2016)

Background: Patients with psoriasis (PsO) suffer from a variety of symptoms. Tools are needed to assess PsO symptoms and signs from the patient’s perspective. Objective: To develop a patient-reported outcome (PRO) measure to assess symptoms and sig

Externí odkaz: https://doaj.org/article/630efae5bd8f4e09afdc20c7b2f9638b

Zobrazit plný text záznamu

Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody for the Treatment of Generalised Pustular Psoriasis: Results from the Phase 2 GALLOP Trial

Autor: Richard B Warren, Adam Reich, Andrzej Kaszuba, Waldemar Placek, Christopher E M Griffiths, Jihao Zhou, Bruce Randazzo, Paul Lizzul, Johann E Gudjonsson

Publikováno v: British Journal of Dermatology.

Background Generalised pustular psoriasis (GPP) is a systemic inflammatory disease that can be severe, debilitating, and life-threatening. Uncontrolled activation of interleukin-36 (IL-36) pro-inflammatory activity may underlie the pathogenesis of GP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6f5020893e6dd7a61ca5ca4b970c6921
https://doi.org/10.1093/bjd/ljad083

Zobrazit plný text záznamu

Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study

Autor: Jerry Bagel, Carle Paul, Kurt Gebauer, Diamant Thaçi, Yin You, Susan Flavin, April W. Armstrong, Lyn Guenther, Andrew Blauvelt, Richard G. Langley, Kristian Reich, Bruce Randazzo, Ming-Chun Hsu

Publikováno v: Journal of Dermatological Treatment. 33:2317-2324

Purpose Guselkumab, an interleukin (IL)-23 inhibitor, effectively treats moderate-to-severe plaque psoriasis. Materials and methods ECLIPSE, was a Phase 3, multicenter, 56-week, double-blinded, active-comparator study of guselkumab vs. secukinumab (I

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ef89250a34d6ef6ab5094331b342c1a
https://doi.org/10.1080/09546634.2021.1959504

Zobrazit plný text záznamu

Safety of guselkumab in patients with moderate‐to‐severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies

Autor: Yaung-Kaung Shen, Kim Papp, Michael Song, Y. Wasfi, Bruce Randazzo, April W. Armstrong, Alexa B. Kimball, Shu Li, Kristian Reich

Publikováno v: British Journal of Dermatology. 180:1039-1049

Background Long-term evaluation is required to confirm the safety profile of newer biologic agents. Objectives To report on pooled safety data from the ongoing VOYAGE 1 (NCT02207231) and VOYAGE 2 (NCT02207244) trials through 100 weeks of follow-up. M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bd852ff047fc6aaa5704822860befe4
https://doi.org/10.1111/bjd.17454

Zobrazit plný text záznamu

Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis : an analysis from VOYAGE 1 and VOYAGE 2

Autor: Jashin J. Wu, Yin You, Melinda Gooderham, Francisco A. Kerdel, Luis Puig, Yaung-Kaung Shen, Bruce Randazzo

Publikováno v: JOURNAL OF DERMATOLOGICAL TREATMENT
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Altres ajuts: Janssen Research and Development (JRD) Introduction: In VOYAGE 1 (NCT02207231) and VOYAGE 2 (NCT02207244), guselkumab, an interleukin-23 blocker, was safe and effective in patients with moderate-to-severe plaque psoriasis. Methods: Pati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c0d92dd42fede3e4f3fc37a5eecff9f
https://ddd.uab.cat/record/269696

Zobrazit plný text záznamu

Extrapolating Pharmacodynamic Effects From Adults to Pediatrics: A Case Study of Ustekinumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis

Autor: Honghui Zhou, Wangda Zhou, Yaowei Zhu, Zhenhua Xu, Chuanpu Hu, Michael Song, Amarnath Sharma, Bruce Randazzo

Publikováno v: Clinical pharmacology and therapeutics. 109(1)

Ustekinumab (STELARA) is a human monoclonal antibody against interleukins-12 and -23 for the treatment of adult and adolescent (≥ 12 to < 18 years of age) patients with moderate-to-severe plaque psoriasis. A phase III study was recently completed i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b5fcb162fe54871b739a5ad1bc8382f
https://pubmed.ncbi.nlm.nih.gov/32865226

Zobrazit plný text záznamu

P279 Guselkumab was more effective than secukinumab in patients with plaque psoriasis and the subset of patients with self-reported PsA in the randomised, double-blind, head-to-head comparison study ECLIPSE over 1 year

Autor: Chetan Karyekar, Laura C. Coates, Ming-Chun Hsu, Joseph F. Merola, Shu Li, Bruce Randazzo, Patricia C Gorecki, Susan Flavin

Publikováno v: Rheumatology. 59

Background Guselkumab (GUS, an antibody against IL-23) and secukinumab (SEC, an antibody against IL-17A) are both approved for the treatment of psoriasis (PsO). Up to 30% of patients with PsO may have psoriatic arthritis (PsA). The ECLIPSE study comp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::df828f21da7a20936f7dbb61c3a91202
https://doi.org/10.1093/rheumatology/keaa111.272

Zobrazit plný text záznamu

Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (≥ 6 to12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study

Autor: K. Barber, Shu Li, Yaowei Zhu, Ming-Chun Hsu, Alan Menter, Lawrence F. Eichenfield, Amy S. Paller, Arjen Nikkels, Sandra Philipp, S. DePrimo, Ian Landells, Michael Song, Bruce Randazzo

Publikováno v: The British journal of dermatologyReferences. 183(4)

BACKGROUND Limited options are available for treatment of paediatric psoriasis. OBJECTIVES To evaluate the efficacy and safety of ustekinumab in paediatric patients with psoriasis (≥ 6 to 100 kg: 90 mg) administered by subcutaneous injection at wee

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddfabe0f77c1bb2c27208a37281916fa
https://pubmed.ncbi.nlm.nih.gov/33015876

Zobrazit plný text záznamu

A comprehensive evaluation of exposure–response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis

Autor: Yang Chen, Zhenling Yao, Bruce Randazzo, Amarnath Sharma, Honghui Zhou, Liping Zhang, Chuanpu Hu, Zhenhua Xu

Publikováno v: Journal of Pharmacokinetics and Pharmacodynamics. 45:523-535

Guselkumab, a human IgG1 monoclonal antibody that blocks interleukin-23, has been evaluated in one Phase 2 and two Phase 3 trials in patients with moderate-to-severe psoriasis, in which disease severity was assessed using Psoriasis Area and Severity

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf59b6f4b1d1ed8dd099e2bda93c0428
https://doi.org/10.1007/s10928-018-9581-1

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání